evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

227 questions · 258 findings · 32 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 68 · 26.4%GRADE not reported 32 · 12.4%Very low 47 · 18.2%Low 70 · 27.1%Moderate 34 · 13.2%High 7 · 2.7%

Prophylactic platelet transfusions with high‐dose schedule vs standard‐dose strategies

Number of participants with at least 1 clinically significant bleeding event up to 30 days from study entry · People with a haematological disorder

Prophylactic platelet transfusions with high‐dose schedule showed no clear difference in number of participants with at least 1 clinically significant… compared with standard‐dose schedule (moderate certainty).

1 finding from 1 review

Prophylactic platelet transfusions with high‐dose schedule vs standard‐dose strategies

Number of participants with WHO grade 3 or 4 bleeding up to 30 days from study entry · People with a haematological disorder

Prophylactic platelet transfusions with high‐dose schedule showed no clear difference in number of participants with WHO grade 3 or 4 bleeding up to 30 days… compared with standard‐dose schedule (low certainty).

1 finding from 1 review

Prophylactic platelet transfusions with high‐dose schedule vs standard‐dose strategies

Mortality from all causes up to 30 days from study entry · People with a haematological disorder

Prophylactic platelet transfusions with high‐dose schedule showed no clear difference in mortality from all causes up to 30 days from study entry compared with standard‐dose schedule (low certainty).

1 finding from 1 review

Summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) vs low‐dose dexamethasone (6 mg to 8 mg)

All‐cause mortality up to 30 days · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19

Summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) showed no clear difference in all‐cause mortality up to 30 days compared with low‐dose dexamethasone (6 mg to 8 mg) (low certainty).

1 finding from 1 review

Summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) vs low‐dose dexamethasone (6 mg to 8 mg)

All‐cause mortality up to 120 days · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19

It is very uncertain whether summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) changes all‐cause mortality up to 120 days compared with low‐dose dexamethasone (6 mg to 8 mg) (very low certainty).

1 finding from 1 review

Summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) vs low‐dose dexamethasone (6 mg to 8 mg)

Clinical improvement: discharged alive ( · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19

Summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) showed no clear difference in clinical improvement: discharged alive ( compared with low‐dose dexamethasone (6 mg to 8 mg) (low certainty).

1 finding from 1 review

Summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) vs low‐dose dexamethasone (6 mg to 8 mg)

Clinical worsening: need for invasive mechanical ventilation, or death at up to day 28 · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19

The review found no eligible studies for this question.

1 finding from 1 review

Intervention not reported

Intervention: high‐dose radiotherapy Comparison: low‐dose radiotherapy Outcome: neurocognitive impairment at 2 years after treatment · people with glioma surviving at least two years

It is very uncertain whether the intervention changes intervention: high‐dose radiotherapy Comparison: low‐dose… (very low certainty).

1 finding from 1 review